Safer Opioids: Separating Pain Relieving Properties from Dangerous Side Effects
News Dec 06, 2017 | Original story from American College of Neuropsychopharmacology

Opioid drugs are the most widely prescribed and effective type of pain medication. But they are highly addictive and have some unpleasant and potentially deadly side effects.
Now a group of researchers, led by Dr. Laura Bohn at The Scripps Research Institute, may have found a way to make opioids safer by separating the drugs' pain relieving effects from their most dangerous side effect, respiratory suppression, which, in very severe cases, causes patients to stop breathing and to die.
All opioid drugs elicit their effects via a small group of protein receptors, called opioid receptors. When an opioid drug binds to its receptor, the receptor is activated and kicks off a chain of reactions that relieve pain. However, the activated opioid receptor can also interact with other nearby signaling proteins, causing side effects such as nausea, sedation, constipation or, most seriously, respiratory suppression.
Dr. Bohn's team has identified several molecules considered to be "biased agonists" because they act at the opioid receptor to stimulate pain relief, but cause less stimulation of the pathway that leads to respiratory suppression. In preliminary studies using mice, the researchers found that the most promising of these compounds provided pain relief levels similar to morphine, but with significantly less respiratory suppression.
Such opioids could help patients and doctors deal with drug tolerance, a frequent complication in which, over time, patients lose sensitivity to the pain-blocking properties of opioids and require higher doses to treat their pain. While biased agonists may be able to be used more safely at higher doses than other opioids, it remains to be seen how other side effect profiles will be affected.
One compound identified as a biased agonist--from the company Trevena--is already showing promising results as it makes its way through clinical trials, and the researchers hope that new compounds with stronger biases will yield even better results.
The recent epidemic of opioid-related deaths has been driven primarily by use of illegally made opioid drugs. However, prescription opioids are playing a significant role in the epidemic. As opioid overdose deaths are mostly due to respiratory suppression, safer prescription opioids, such as those being developed by Dr. Bohn, could also ultimately decrease the number of deaths caused by abusing prescription opioids.
This article has been republished from materials provided by American College of Neuropsychopharmacology. Note: material may have been edited for length and content. For further information, please contact the cited source.
RELATED ARTICLES
Artificial Leaf Acts as a Mini Medicine Factory
NewsUsing sunlight for sustainable and cheap production of, for example, medicines. The 'mini-factory' in the form of a leaf that was presented in 2016 showed that it is possible. Now researchers have come with an improved version: their 'mini-factory' is now able to keep production at the same level, irrespective of the variation in sunlight due to cloudiness or time of the day.
READ MORESheep Toxin Could Cause MS
NewsExposure to a toxin primarily found in sheep could be linked to the development of multiple sclerosis (MS) in humans, new research suggests.
READ MORECompound Offers Pain-relief of Opioids Without Addictive Properties
NewsResearchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018
Login
You must be logged in to post a comment.